268 related articles for article (PubMed ID: 26302032)
1. Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature.
Polizzi S; Mahajan VB
J Ocul Pharmacol Ther; 2015 Dec; 31(10):605-10. PubMed ID: 26302032
[TBL] [Abstract][Full Text] [Related]
2. Inadvertent use of bevacizumab in pregnant women with diabetes mellitus type 1.
Polizzi S; Ferrara G; Restaino S; Rinaldi S; Tognetto D
J Basic Clin Physiol Pharmacol; 2015 Mar; 26(2):161-3. PubMed ID: 25153234
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
5. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
6. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
8. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
[TBL] [Abstract][Full Text] [Related]
12. Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide.
Morshedi RG; Ricca AM; Wirostko BM
J Glaucoma; 2016 Mar; 25(3):291-300. PubMed ID: 25318578
[TBL] [Abstract][Full Text] [Related]
13. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
14. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
van der Reis MI; La Heij EC; De Jong-Hesse Y; Ringens PJ; Hendrikse F; Schouten JS
Retina; 2011 Sep; 31(8):1449-69. PubMed ID: 21817960
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature.
Ong AY; Kiire CA; Frise C; Bakr Y; de Silva SR
Eye (Lond); 2024 Apr; 38(5):951-963. PubMed ID: 37980398
[TBL] [Abstract][Full Text] [Related]
17. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
18. Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
Berkowitz ST; Patel S
Ophthalmol Retina; 2021 Apr; 5(4):357-364. PubMed ID: 32818623
[TBL] [Abstract][Full Text] [Related]
19. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
[TBL] [Abstract][Full Text] [Related]
20. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
